I think with several cases bought back from the dead the US govt...

I think with several cases bought back from the dead the US govt will find a way to comprimise with gsk on testing design and push this forward - it's very interesting that relenza iv was able to reverse viral replication so suddenly in an advanced patient- it's systemic potency must be far greater than tamiflu to have this outcome where no tamiflu resistance was present- as posted above is a very important point. Anyone know if the iv formulation is the same as the powder- or does it need to have something added to get a iv format- and how does this affect cost/ rate of production?
If it's as easy as adding the existing formulation to an iv line - it could end up being a blockbuster.

Then how about IV Lani???